FIELD: medicine.
SUBSTANCE: versions of antibodies bound with glypican-3 in a site with amino acid residues 1-563 are offered. Each version is characterised by the fact that it contains three CDRs of a light chain and three CDRs of a heavy chain. There are described: coding polynucleotide, and also a based expression and a host cell on the basis of the vector. There are disclosed: a method of producing the antibody with using a host cell, a cell growth inhibitor on the basis of the antibody, versions of application of the antibody for treating cancer or hepatoma. There is described peptide for producing glypican-3 antibodies containing residues 546-551 of glypican-3. The offered new antibodies exhibit higher cytotoxicity as compared with known glypican-3 antibodies and are specific to a certain site of glypican-3.
EFFECT: invention use can find further application in cancer therapy.
16 cl, 20 dwg, 2 tbl, 27 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY TO GLYPICAN 3 | 2011 |
|
RU2611751C2 |
| CELL DAMAGE INDUCING THERAPEUTIC MEDICINAL PRODUCT FOR ANTICANCER THERAPY | 2017 |
|
RU2746754C2 |
| MEDICATION FOR TREATMENT OF LIVER CANCER | 2009 |
|
RU2523897C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2812875C1 |
| GLYPICAN-3 ANTIBODY AND USE THEREOF | 2016 |
|
RU2744245C2 |
| GPC3-TARGETED DRUG WHICH IS ADMINISTERED TO PATIENT SENSITIVE TO GPC3 DRUG-TARGETING THERAPY | 2013 |
|
RU2707882C2 |
| ANTI-CXCR4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2014 |
|
RU2675516C2 |
| ANTI-GLYPICAN 3-ANTIBODY HAVING MODIFIED SUGAR CHAIN | 2005 |
|
RU2451030C2 |
| MEDICINAL AGENT CONTAINING PHOSPHOLIPASE D4 ANTIBODY | 2014 |
|
RU2709741C2 |
| MODIFIED EXOTOXIN A PSEUDOMONADES | 2014 |
|
RU2687143C2 |
